SNRIs: mechanism of action and clinical features

References

• Rossby SP, Manier DH, Liang S, Nalepa I, Sulser E Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Int. .1. NeuropsychopharmacoL 2(1), 1–8 (1999).
   Google Scholar
• Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of midalcipran (F 2207), 1-pheny1-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology24(12), 1211–1219 (1985).
   Google Scholar
• Patat A, Troy S, Burke J. Absolute bioavailability and electroencephalographic effects of conventionnal and extended-release formulation of venlafaxine in healthy subjects. .1. Clin. Pharmacol. 38, 256–267 (1998).
   Google Scholar
• Samuelian JC, Hackett D. A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in out-patients with major depression. J. Psychopharmacol. 12(3), 274–279 (1998).
   Web of Science ®Google Scholar
• Lecrubier Y, Bourin M, Moon CA et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psych. Scand. 95, 485–493 (1997).
   PubMed Web of Science ®Google Scholar
• Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in out-patients with major depression. .1. Clin. Psych. 59,352-357 (1998).
   Google Scholar
• Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Affect Disord 56,171–181 (1999).
   PubMed Web of Science ®Google Scholar
• Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin. Psychopharmacol 9,139–143 (1994).
   Google Scholar
• Einarson TR, Arikian SR, Casiano J et aL Comparison of extended-release venlafaxine, selective serotonin re-uptake inhibitors and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clin. The: 21(2), 296–308 (1999).
   Google Scholar
• ••Very interesting paper which presents a meta-analysis involving a high number of patients and demonstrating a significant greater efficacy for venlafaxine versus SSRIs and TCAs.
   Google Scholar
• Entsuah R, Zajecka JM, Nierenberg AA et aL Comparative remission analysis between venlafaxine and paroxetine. Presented at the American Psychiatric Association Annual Meeting, May 5–10, New Orleans, LA, USA (2001). iiSmith D, Dempster C, Glanville J et aL Efficacy and tolerability of venlafaxine compared with selective serotonin re-uptake inhibitors and other antidepressants: A meta-analysis. BE .1. Psych. 180,396-404 (2002).
   Google Scholar
• ••Very interesting paper which presents a recent meta-analysis with a large sample and shows a significantly greater efficacy of venlafaxine versus SSRls, but not versus TCAs.
   Google Scholar
• Poirier ME Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br. Psych. 175,12-16 (1999).
   Google Scholar
• Ferrier IN. Treatment of major depression: Is improvement enough? .I. Clin. Psych. 60\(Suppl. 6), 10–14 (1999).
   Google Scholar
• Thase ME, Sullivan LR. Relapse and recurrence of depression: A practical approach for prevention. CNS Drugs 4, 261–277 (1995).
   Web of Science ®Google Scholar
• Entsuah AR, Gorman JM. Global benefit— risk assessment of antidepressants: Venlafaxine XR and fluoxetine. .1. Psych. Res. 36 (3), 111–118 (2002).
   Google Scholar
• Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administred venlafaxine, selective re-uptake inhibitors, or placebo. .1. Clin. Psych. 62(11), 869–877 (2001).
   Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remissions rates during treatment with venlafaxine or selective re-uptake inhibitors. BE .1. Psych. 178,234-241 (2001).
   Google Scholar
• Poirier ME Venlafaxine versus paroxetine in the treatment of resistant depression. BioL Psych. 42,243S (1997).
   Google Scholar
• Frank E, Kupfer DJ, Perel JM et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance of reccurent depression. .1. Affect. Disord 27, 139–145 (1993).
   Google Scholar
• Entsuah AR, Rudolph RL, Hackett D et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates. Int. Clin. Psych. 11,137–145 (1996).
   PubMed Web of Science ®Google Scholar
• Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed out-patients. .1. Affect. Disord 47, 55–62 (1998).
   Google Scholar
• ••Meta-analysis of 1032 patients which demonstrates the efficacy of milnacipran in MDD treatment with a response as efficient as TCAs and greater than SSRls.
   Google Scholar
• Cunningham LA for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended-release (XR) and venlafaxine immediate-release (IR) in out-patients with major depression. Ann. Clin. Psych. 9,157-164 (1997).
   Google Scholar
• ••Meta-analysis of milnacipran efficacy in MDD with a large evaluation of adverse side effects detected during the different trials, reinforced by pharmacovigilance observations.
   Google Scholar
• Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in out-patients with major depression. Clin. Psych. 58,393–398 (1997).
   Google Scholar
• Silverstone PH, Ravindran A for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in out-patients with depression and anxiety. .1. Clin. Psych. 60,22-28 (1999).
   Google Scholar
• Evans D, Nemeroff C, Thase M et aL Improvement in social activity level, general life and cognitive functionning with venlafaxine versus fluoxetine in in-patients with melancholic depression. Eur. Psych. 17\(Suppl. 1), 194 (2002).
   Google Scholar
• Kahn N, Nemeroff C, Wan G et aL Improvement in general life functionning with venlafaxine versus fluoxetine in out-patients with major depression. Eur. Psych. 17\(Suppl. 1), 194 (2002).
   Google Scholar
• Puech A, Montgomery SA, Prost JF et al. Milnacipran, a new serotonin and noradrenaline re-uptake inhibitor: An overview of its antidepressant activity and clinical tolerability. Int. Clin. Psychopharmacol. 12,99–108 (1997).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Prost JF, Solles A et aL Efficacy and tolerability of milnacipran: An overview. Int. Clin. Psychopharmacol. 11 (Suppl. 4), 47–51 (1996).
   Google Scholar
• Guelfi JD, Ansseau M, Corruble E et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed in patients. Int. Clin. Psychopharmacol 13(3), 211–228 (1998).
   Google Scholar
• Clerc G and the milnacipran/fluvoxamine group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline re-uptake inhibitor: A comparison with fluvoxamine. mt. Clin. Psychopharmacol 16,145–151 (2001).
   Google Scholar
• Lopez-Ibor J, Guelfi JD, Pletan Y et al Milnacipran and selective serotonin re-uptake inhibitors in major depression. hit. Clin. Psychopharmacolll (Suppl. 4), 41–46 (1996).
   Google Scholar
• Rouillon F, Warner B, Pezous N et al. Milnacipran efficacy in the prevention of recurrent depression: A 12-month placebo-controlled study. Int. Clin. Psychopharmacol 15,133–140 (2000).
   Google Scholar
• Rouillon F, Berdeaux G, Bisserbe JC et al. Prevention of recurrent depressive episodes with milnacipran: Consequences on quality of life. Affect. Disord. 58(3), 171–180 (2000).
   PubMed Web of Science ®Google Scholar
• Davidson JRT, DuPont RL, Hedges D et al. Efficacy, safety and tolerability of Venlafaxine ER and buspirone in out-patients with generalized anxiety disorder. J. Clin. Psych. 60,528–535 (1999).
   Google Scholar
• Gelenberg AJ, Lyliard RB, Rudolph RL. Efficacy of Venlafaxine ER capsules in nondepressed out-patients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283,3082–3088 (2000).
   Google Scholar
• Rickels K, Pollack MH, Sheehan DV et al. Efficacy of extended-release venlafaxine in non-nondepressed out-patients with generalized anxiety disorder. Am. J. Psych. 157,968–974 (2000).
   PubMed Web of Science ®Google Scholar
• Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J. Clin. Psych. 62,523–529 (2001).
   Google Scholar
• Meoni P, Salinas E, Brault Y et al. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J. Clin. Psych. 62,888–893 (2001).
   Google Scholar
• •Pooled analysis of five controlled trials for venlafaxine in GAD which confirms the efficacy of venlafaxine in this indication and analyzes the improvement in different symptoms of this disorder.
   Google Scholar
• Katz IR, Reynolds CF, Alexopoulos GS et al. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: Pooled analysis of five randomized placebo-controlled clinical trials. J. Am. Ceriat. Soc. 50,18–25 (2002).
   Google Scholar
• Pollack MH, Worthingtor JJ, Otto MW eta]. Venlafaxine for panic disorder: Result from a double-blind, placebo-controlled study. fiychopharmacol Bull 32,667–670 (1996).
   PubMed Web of Science ®Google Scholar
• Shweizer E, Weise L, Clary C et al. Placebo- controlled trial of venlafaxine for the treatment of major depression. J. Clin. Psychopharmacol 11, 233–236 (1991).
   PubMed Web of Science ®Google Scholar
• Guelfi JD, White C, Hackett D etal. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psych. 56,450–458 (1995).
   Google Scholar
• Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: Pattern analysis in intent-to-treat patients. Thec 20(3), 517–526 (1998).
   Google Scholar
• Benkert O, Grunder G, Wetzel H eta]. A randomized double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in in-patients with major depression and melancholia. J. Psych. Res. 30(6), 441–451 (1996).
   Google Scholar
• Biter P Pharmacology of rapid-onset antidepressant treatment strategies. J. Clin. Psych. 62 (Suppl. 15), 12–17 (2001).
   Google Scholar
• Muth EA, Moyer JA, Haskins JT et al Biochemical, neurophysiological and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23,191-199 (1991).
   Google Scholar
• Neliat G, Bodinier MC, Panconi E eta]. Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin re-uptake inhibitor, on the beta-adrenoreceptor-linked adenyl cyclase system in the rat cerebral cortex. Neuropsychopharmacol 35,589–593 (1996).
   Google Scholar
• Derivan A, Entsuah AR, Kikta D. Venlafaxine: Measuring the onset of antidepressant action. Psychopharmacol Bull. 31(2), 439–447 (1995).
   PubMedGoogle Scholar
• Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. J. Clin. Psychopharmacol 16\(Suppl. 2), 54-59S (1996).
   Google Scholar
• ••Interesting study of the adverse side effectsof venlafaxine on a large sample of patients from controlled and open trials which evaluates the rate of occuring of frequent and rarer events during the treatment.
   Google Scholar
• Rudolph RL, Fabre LF, Feighner JP et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J. Clin. Psych. 59,116–122 (1998).
   Google Scholar
• Einarson A, Fatoye B, Sarkar M et al Pregnancy outcome following gestional exposure to venlafaxine: A multicenter prospective controlled study. Am. I Psych. 158(10), 1728–1738 (2001).
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Rigney U, Stanley N et al. Pharmacodynamics of milnacipran in youg and elderly volunteers. BE J. Pharmacol 49(2), 118–125 (2000).
   Web of Science ®Google Scholar
• Greenberg PE, Stiglin LE, Finkelstein SM et al. The economic burden of depression in 1990.1 Clin. Psych. 54,405-418 (1993).
   Google Scholar
• Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmalogical treatment. Bi:j fiych. 164,665–673 (1994).
   PubMed Web of Science ®Google Scholar
• Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kindom. PharmacoEconomics 18(2), 143–148 (2000).
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Sullivan EM, Frank RG eta]. Medical ressource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin re-uptake inhibitor therapy for depression. PharmacoEconomics 15(5), 495–505 (1999).
   Google Scholar
• Dardennes R, Berdeaux G, Lafuma A et al Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: A modeling approach. Eur. Psych. 14,152–162 (1999).
   Google Scholar
• Bourin M. Psychopharmacological profile of venlafaxine. Encephale 2,21-22; discussion 23–25 (1999).
   Google Scholar